• Explore /
  • Poster
  • / CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.

CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.

Abstract Poster

Authors

null

Jianming Xu

Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of People's Liberation Army, Beijing, China

Jianming Xu , Bangwei Cao , Kangsheng Gu , Yuxian Bai , Wei Li , Jingdong Zhang , Caigang Liu , Zuoxing Niu , Liangming Zhang , Haijun Zhong , SuXia Luo , Jian-Wei Zhou , Tianshu Liu , Yanhong Gu , Jingguan Lin , Yanhong Deng , Chuangqi Chen , Yunfeng Li , Xiuli Yang , Bihui Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT04466254

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3574)

DOI

10.1200/JCO.2022.40.16_suppl.3574

Abstract #

3574

Poster Bd #

368

Abstract Disclosures

Similar Posters

First Author: Heinz-Josef Lenz

First Author: Heinz-Josef Lenz

Poster

2014 Gastrointestinal Cancers Symposium

A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05).

A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05).

First Author: Tatsuro Yamaguchi

First Author: Ho Min Kim